CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
Open Access
- 31 October 2017
- journal article
- research article
- Published by Informa UK Limited in OncoImmunology
- Vol. 7 (2), e1386361
- https://doi.org/10.1080/2162402x.2017.1386361
Abstract
Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα “don't eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Single agent treatment with RTX-CD47 triggered significant phagocytic removal of CD20pos/CD47pos malignant B-cells, but not of CD20neg/CD47pos cells, and required no pro-phagocytic FcR-mediated signaling. Importantly, treatment with RTX-CD47 synergistically enhanced the phagocytic elimination of primary malignant B cells by autologous phagocytic effector cells as induced by therapeutic anticancer antibodies daratumumab (anti-CD38), alemtuzumab (anti-CD52) and obinutuzumab (anti-CD20). In conclusion, RTX-CD47 blocks CD47 “don't eat me” signaling by cancer cells in a CD20-directed manner with essentially no activity towards CD20neg/CD47pos cells and enhances the activity of therapeutic anticancer antibodies directed to B-cell malignancies.Keywords
This publication has 19 references indexed in Scilit:
- Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemiaInternational Journal of Applied and Basic Medical Research, 2015
- A CD47‐blocking TRAIL fusion protein with dual pro‐phagocytic and pro‐apoptotic anticancer activityBritish Journal of Haematology, 2013
- Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell responseProceedings of the National Academy of Sciences of the United States of America, 2013
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic LeukemiaCancer Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Species- and cell type-specific interactions between CD47 and human SIRPαBlood, 2006
- A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cellsBiochemical and Biophysical Research Communications, 2004